NASDAQ · Biotechnology

KURA (KURA) Stock

$9.57 +3.13% NASDAQ: KURA Healthcare

Valuation

MetricValue
Price$9.57
Market Cap$849.57M
P/E Ratio-2.90
P/B Ratio4.70
P/S Ratio11.40
EPS (TTM)$-3.18
52-Week High$12.49
52-Week Low$5.45
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-160.34%
ROA-37.80%
ROCE-174.71%
Gross Margin-453.73%
Operating Margin-453.73%
Net Margin-4.11%
Debt/Equity0.22
Current Ratio6.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$54.0M$67.0M
Operating Profit$-131.0M$-140.0M$-166.0M$-193.0M$-304.0M
Net Profit$-130.0M$-136.0M$-153.0M$-174.0M$-279.0M
EPS$-1.97$-2.03$-2.08$-2.02$-3.18
Op Margin———-358.6%-449.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$534.0M$456.0M$449.0M$760.0M$738.0M
Total Liabilities$27.0M$36.0M$52.0M$347.0M$564.0M
Cash$91.0M$52.0M$37.0M$224.0M$149.0M
Borrowings$7.0M$14.0M$17.0M$17.0M$20.0M

Latest News

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 GlobeNewswire · Jul 14, 2026 Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story? Simply Wall St. · Jul 7, 2026 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 3, 2026 Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? Insider Monkey · Jun 30, 2026 Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients MT Newswires · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-105.0M$-110.0M$-125.0M$134.0M$-64.0M
Investing Cash Flow$-128.0M$32.0M$15.0M$-102.0M$-20.0M
Financing Cash Flow$-1.0M$4.0M$1.0M$9.0M$0
Net Cash Flow$-235.0M$-39.0M$-14.0M$187.0M$-75.0M
Free Cash Flow$-106.0M$-111.0M$-125.0M$134.0M$-71.0M

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPL $325.13 +2.61% 35.78 $4.78T 0.34%
MSFT $501.02 -1.24% 27.58 $3.72T 0.73%
GOOGL $335.02 -1.28% 16.98 $4.05T 0.26%
AMZN $254.92 -1.87% 20.66 $2.74T 0.00%
META $578.54 +1.08% 21.41 $1.47T 0.36%

About KURA

KURA is led by CEO Troy Edward Wilson, employs 192 people, headquartered in US, publicly traded since 2015.

KURA stock trades at $9.57 with a market capitalization of $849.57M. The stock is valued at a price-to-earnings (P/E) ratio of -2.90, price-to-book of 4.70, price-to-sales of 11.40. Over the past 52 weeks the stock has ranged between $5.45 and $12.49, and currently trades 23.4% below its 52-week high.

On profitability, KURA generates a return on equity (ROE) of -160.34%, return on capital employed of -174.71%, an operating margin of -453.73%, a net profit margin of -4.11%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides